Evidence map›Paper›PMID 35997796›Full record

ArticleEuropean journal of preventive cardiology2022

Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association.

Alberto Ortiz, Christoph Wanner, Ron Gansevoort, ERA Council

Registry-linked trialOpen access · greenAbstract readConsensus Statement
PubMed Publisher
In one paragraph

Article in European journal of preventive cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06444711 (A Randomised Clinical Trial for OPTIMISation of Cardio-renal-metabolic-pulmonary Disease Guideline Adherence in High Risk Community Dwelling Individuals and Evaluation of Outcomes), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06444711 naactive not recruitingnot on this mapstarted 2025, after this paper: background citation

A Randomised Clinical Trial for OPTIMISation of Cardio-renal-metabolic-pulmonary Disease Guideline Adherence in High Risk Community Dwelling Individuals and Evaluation of Outcomes

TypeinterventionalSponsorUniversity of LeedsRan2025 to 2045Enrolled138ConditionsCardiovascular Diseases, Renal Disease, Metabolic Disease, Pulmonary DiseaseArmsNICE guidance
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. The Synergistic Treatment of Heart and Kidney Disease.Deutsches Arzteblatt international · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Observational
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 11 institutions in 9 countries.

Alberto OrtizIIS-Fundacion Jimenez Diaz- UAM, Madrid, Spain.ORCID 0000-0002-9805-9523
Christoph WannerDepartment of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany.ORCID 0000-0001-9507-5301
Ron GansevoortDepartment of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0002-3223-0906
ERA Council
Hospital Universitario Fundación Jiménez Díaz · ESUniversitätsklinikum Würzburg · DEUniversity Medical Center Groningen · NLAristotle University of Thessaloniki · GRHanze University of Applied Sciences · NLMedical University of Graz · ATOspedale Maggiore · ITSaarland University · DEUniversitat Autònoma de Barcelona · ESUniversity of Milan · ITUniversity of Sheffield · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractThe European Society of Cardiology 2021 guideline on cardiovascular (CV) disease (CVD) prevention in clinical practice has major implications for both CV risk screening and kidney health of interest to primary care physicians, cardiologists, nephrologists, and other professionals involved in CVD prevention. The proposed CVD prevention strategies require as first step the categorization of individuals into those with established atherosclerotic CVD, diabetes, familiar hypercholesterolaemia, or chronic kidney disease (CKD), i.e. conditions that are already associated with a moderate to very-high CVD risk. This places CKD, defined as decreased kidney function or increased albuminuria as a starting step for CVD risk assessment. Thus, for adequate CVD risk assessment, patients with diabetes, familiar hypercholesterolaemia, or CKD should be identified by an initial laboratory assessment that requires not only serum to assess glucose, cholesterol, and creatinine to estimate the glomerular filtration rate, but also urine to assess albuminuria. The addition of albuminuria as an entry-level step in CVD risk assessment should change clinical practice as it differs from the current healthcare situation in which albuminuria is only assessed in persons already considered to be at high risk of CVD. A diagnosis of moderate of severe CKD requires a specific set of interventions to prevent CVD. Further research should address the optimal method for CV risk assessment that includes CKD assessment in the general population, i.e. whether this should remain opportunistic screening or whether systematic screening.

Indexed as

Cardiovascular DiseasesDiabetes MellitusRenal Insufficiency, ChronicHeart Disease Risk FactorsHumansKidneyRisk Factorsalbuminuriacardiovascular riskGFRpreventionrisk prediction

Identifiers

PMID35997796
OpenAlexW4292749610

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.